Spatial transcriptomics reveals tumor microenvironment–driven subtypes of invasive lobular carcinoma

M Matteo Serra (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) M Mattia Rediti (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) L Laetitia Collet (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) F Frédéric Lifrange (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) D David Venet (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) N Nicola Occelli (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) A Andreas Papagiannis (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) D Delphine Vincent (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) G Ghizlane Rouas (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) D Denis Larsimont (Department of Pathology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) M Miikka Vikkula (Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain) F Francois P. Duhoux (Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique (pôle MIRO)) F Françoise Rothé (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles) C Christos Sotiriou (Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles)

Abstract

Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer and displays distinct clinical and biological behavior compared to breast cancer of no special type. However, current molecular classifications largely overlook its complex spatial organization and tumor microenvironment (TME). Here, we performed spatial transcriptomics on 43 hormone receptor-positive, HER2-negative (HR+/HER2−) ILC tumors with detailed morphological annotation and long-term clinical follow-up. By integrating spatial gene expression with histology and single-cell deconvolution, we characterized the composition and architecture of the TME and revealed high inter- and intratumor heterogeneity. Spatial clustering uncovered cell populations and pathways linked to clinical outcome. We then developed a multimodal classification of ILC by integrating gene expression, morphology, and spatial metrics, identifying four distinct subtypes: normal/stroma-enriched (NSE), proliferative (P), androgen receptor-enriched (ARE), and metabolic/immune-enriched (MIE). These subtypes, collectively termed ILC4TME, reflect the interplay between tumor and microenvironmental features. Gene signatures derived from the spatial data enabled subtype assignment in external bulk RNA-seq and microarray datasets (SCAN-B, METABRIC), revealing reproducible biology and significant associations with survival. In multivariable models, ILC4TME retained prognostic value beyond established gene signatures and clinicopathological variables. Notably, the P subtype was linked to poor prognosis, even in patients treated with endocrine therapy alone, while the NSE subtype was associated with favorable outcomes. Our findings uncover spatial and cellular heterogeneity in ILC that is not captured by existing classification approaches, offering a refined framework for risk stratification and therapeutic targeting based on tumor microenvironment architecture.

Article Details

Volume / Issue Vol. 123, Issue 6
Published February 10, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (14)

M

Matteo Serra

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

M

Mattia Rediti

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

L

Laetitia Collet

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

F

Frédéric Lifrange

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

D

David Venet

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

N

Nicola Occelli

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

A

Andreas Papagiannis

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

D

Delphine Vincent

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

G

Ghizlane Rouas

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

D

Denis Larsimont

Department of Pathology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

M

Miikka Vikkula

Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain

F

Francois P. Duhoux

Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique (pôle MIRO)

F

Françoise Rothé

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles

C

Christos Sotiriou

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles